Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Abstract Background Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio has been reported to impact prognosis and response to antiestrogen endocrine therapy (ET). Methods We assessed whether A...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4239-3 |
| _version_ | 1828380109770326016 |
|---|---|
| author | Giuseppe Bronte Andrea Rocca Sara Ravaioli Maurizio Puccetti Maria Maddalena Tumedei Emanuela Scarpi Daniele Andreis Roberta Maltoni Samanta Sarti Lorenzo Cecconetto Anna Fedeli Elisabetta Pietri Valeria De Simone Silvia Asioli Dino Amadori Sara Bravaccini |
| author_facet | Giuseppe Bronte Andrea Rocca Sara Ravaioli Maurizio Puccetti Maria Maddalena Tumedei Emanuela Scarpi Daniele Andreis Roberta Maltoni Samanta Sarti Lorenzo Cecconetto Anna Fedeli Elisabetta Pietri Valeria De Simone Silvia Asioli Dino Amadori Sara Bravaccini |
| author_sort | Giuseppe Bronte |
| collection | DOAJ |
| description | Abstract Background Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio has been reported to impact prognosis and response to antiestrogen endocrine therapy (ET). Methods We assessed whether AR in primary tumors and/or matched metastases is a predictor of efficacy of first-line ET in advanced BC. Patients who had received first-line ET (2002–2011) were recruited, while those given concomitant chemotherapy or trastuzumab or pretreated with > 2 lines of chemotherapy were excluded. ER, progesterone receptor (PgR), Ki67 and AR expression were assessed by immunohistochemistry, and HER2 mainly by fluorescent in-situ hybridization. Cut-offs of 1 and 10% immunostained cells were used to categorize AR expression. Results Among 102 evaluable patients, biomarkers were assessed in primary tumors in 70 cases and in metastases in 49, with 17 patients having both determinations. The overall concordance rate between primary tumors and metastases was 64.7% (95% CI 42%-87.4%) for AR status. AR status did not affect TTP significantly, whereas PgR and Ki67 status did. AR/PgR ≥0.96 was associated with a significantly shorter TTP (HR = 1.65, 95% CI 1.05-2.61, p = 0.028). AR status in primary tumors or metastases was not associated with progressive disease (PD) as best response. In contrast, Ki67 ≥ 20% and PgR < 10% showed a statistically significant association with PD as best response. Conclusions AR expression does not appear to be useful to predict the efficacy of ET in advanced BC, whereas Ki67 and PgR exert a greater impact on its efficacy. |
| first_indexed | 2024-12-10T03:52:43Z |
| format | Article |
| id | doaj.art-a1e83023ff4f413dbf5030f2920dfd22 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-10T03:52:43Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-a1e83023ff4f413dbf5030f2920dfd222022-12-22T02:03:13ZengBMCBMC Cancer1471-24072018-03-011811810.1186/s12885-018-4239-3Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?Giuseppe Bronte0Andrea Rocca1Sara Ravaioli2Maurizio Puccetti3Maria Maddalena Tumedei4Emanuela Scarpi5Daniele Andreis6Roberta Maltoni7Samanta Sarti8Lorenzo Cecconetto9Anna Fedeli10Elisabetta Pietri11Valeria De Simone12Silvia Asioli13Dino Amadori14Sara Bravaccini15Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSS. Maria delle Croci HospitalIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSDepartment of Pathology, Morgagni-Pierantoni HospitalIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSAbstract Background Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio has been reported to impact prognosis and response to antiestrogen endocrine therapy (ET). Methods We assessed whether AR in primary tumors and/or matched metastases is a predictor of efficacy of first-line ET in advanced BC. Patients who had received first-line ET (2002–2011) were recruited, while those given concomitant chemotherapy or trastuzumab or pretreated with > 2 lines of chemotherapy were excluded. ER, progesterone receptor (PgR), Ki67 and AR expression were assessed by immunohistochemistry, and HER2 mainly by fluorescent in-situ hybridization. Cut-offs of 1 and 10% immunostained cells were used to categorize AR expression. Results Among 102 evaluable patients, biomarkers were assessed in primary tumors in 70 cases and in metastases in 49, with 17 patients having both determinations. The overall concordance rate between primary tumors and metastases was 64.7% (95% CI 42%-87.4%) for AR status. AR status did not affect TTP significantly, whereas PgR and Ki67 status did. AR/PgR ≥0.96 was associated with a significantly shorter TTP (HR = 1.65, 95% CI 1.05-2.61, p = 0.028). AR status in primary tumors or metastases was not associated with progressive disease (PD) as best response. In contrast, Ki67 ≥ 20% and PgR < 10% showed a statistically significant association with PD as best response. Conclusions AR expression does not appear to be useful to predict the efficacy of ET in advanced BC, whereas Ki67 and PgR exert a greater impact on its efficacy.http://link.springer.com/article/10.1186/s12885-018-4239-3Androgen receptorAdvanced breast cancerAnti-estrogen therapyEndocrine therapyAR/ER ratio |
| spellingShingle | Giuseppe Bronte Andrea Rocca Sara Ravaioli Maurizio Puccetti Maria Maddalena Tumedei Emanuela Scarpi Daniele Andreis Roberta Maltoni Samanta Sarti Lorenzo Cecconetto Anna Fedeli Elisabetta Pietri Valeria De Simone Silvia Asioli Dino Amadori Sara Bravaccini Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? BMC Cancer Androgen receptor Advanced breast cancer Anti-estrogen therapy Endocrine therapy AR/ER ratio |
| title | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
| title_full | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
| title_fullStr | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
| title_full_unstemmed | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
| title_short | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
| title_sort | androgen receptor in advanced breast cancer is it useful to predict the efficacy of anti estrogen therapy |
| topic | Androgen receptor Advanced breast cancer Anti-estrogen therapy Endocrine therapy AR/ER ratio |
| url | http://link.springer.com/article/10.1186/s12885-018-4239-3 |
| work_keys_str_mv | AT giuseppebronte androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT andrearocca androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT sararavaioli androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT mauriziopuccetti androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT mariamaddalenatumedei androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT emanuelascarpi androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT danieleandreis androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT robertamaltoni androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT samantasarti androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT lorenzocecconetto androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT annafedeli androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT elisabettapietri androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT valeriadesimone androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT silviaasioli androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT dinoamadori androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy AT sarabravaccini androgenreceptorinadvancedbreastcancerisitusefultopredicttheefficacyofantiestrogentherapy |